Comparing the risk of hepatitis B virus reactivation between direct‐acting antiviral therapies and interferon‐based therapies for hepatitis C
N. Kawagishi; G. Suda; M. Onozawa; M. Kimura; O. Maehara; M. Ohara; T. Izumi; M. Umemura; J. Ito; M. Nakai; T. Sho; M. Natsuizaka; K. Morikawa; K. Ogawa; N. Sakamoto
Author Information: Department of Gastroenterology and Hepatology
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.